Category: Tech

Tech Innovations for Disaster Resilience

Tech Innovations for Disaster Resilience Introduction Disasters can strike at any moment, causing widespread devastation and loss of life. However, with advancements in technology, there...

DCR-STAT3 is a Dicerna Pharmaceuticals drug candidate for the treatment of solid tumors. It is a small interfering RNA (siRNA) that targets the STAT3 gene. STAT3 is a transcription factor that is involved in cell growth and survival. By targeting STAT3, DCR-STAT3 could inhibit the growth and survival of cancer cells. DCR-STAT3 has been shown to be effective in preclinical studies in a variety of solid tumors. In a Phase 1 clinical trial, DCR-STAT3 was well-tolerated and showed promising antitumor activity. A Phase 2 clinical trial is currently underway to evaluate the efficacy and safety of DCR-STAT3 in patients with advanced solid tumors. Based on the available data, DCR-STAT3 has a high likelihood of approval for the treatment of solid tumors.

DCR-STAT3 is under clinical development by Dicerna Pharmaceuticals for Solid Tumor and has a 54% phase transition success rate (PTSR) indication benchmark for progressing into...

OtterBox Cases 50% Off for Black Friday

**OtterBox is offering Black Friday discounts on many of its cases, including the Commuter Series for the iPhone 14 and 13 series which are now...

OpenAI fires Sam Altman in a huge upset.

OpenAI’s board of directors has decided to remove CEO Sam Altman, citing a lack of candor in his communications with the board. The board is...